PhaseBio is a clinical-stage biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease. The company uses its proprietary recombinant biopolymers called elastin-like polypeptides (ELPs) to improve the stability, bioavailability, activity and ease of administration of proteins and peptides, with the goal of achieving greater potency, fewer side effects and better patient compliance. Efficient production in E. coli ensures low cost of goods.
PhaseBio’s lead drug candidate, PB1023, is currently being evaluated in a phase 2b clinical trial for the treatment of hyperglycemia associated with type 2 diabetes, with potential for future use in the treatment of obesity. Our second drug candidate, Vasomera™, is currently being evaluated in a phase 1 clinical trial and has exciting potential for use in the treatment of pulmonary arterial hypertension (PAH) and heart failure. Our third program, Insumera, a basal insulin based on native human insulin, will enter clinical trials in early 2013.
PhaseBio is based in Malvern, Pennsylvania..
Funding Rounds (6) - $144.12MUpdate
Current Team (6)Update
|Mar 28, 2016||WRAL Techwire - Duke buys back PhaseBio's anticancer option|
|Mar 13, 2015||StrictlyVC - StrictlyVC: March 13, 2015|
|Mar 12, 2015||Dow Jones Venture Wire - PhaseBio Picks Up $40M Series C Led By AstraZeneca|
|Mar 12, 2015||Fierce Biotech - AstraZeneca gambles on a $40M round for diabetes/cardio biotech PhaseBio|
|Mar 12, 2015||FinSMEs - PhaseBio Pharmaceuticals Secures $40M in Series C Funding|
|Mar 12, 2015||WSJ Blogs - The Daily Startup: Memebox Raises $29M for Beauty-Product Sales|
|Mar 18, 2014||SEC - SEC FORM D|
|Aug 13, 2013||SEC - SEC FORM D/A|
1 Great Valley Parkway
Malvern, Pennsylvania 19355